tbuckley/cabot-search huggingface dataset:
Postoperative Fibrinolysis
Authors: E. T. O'Brien
Journal: BMJ (1970)

<h3>Abstract</h3> Gamma-irradiation of blood products is mandatory to avoid graft versus host disease in patients with immunosuppressed clinical conditions. Pathogen inactivation techniques were implemented to optimize safe blood component supply. The INTERCEPT treatment uses amotosalen together with UVA irradiation. The functional and molecular implications of these essential treatments have not yet been systematically assessed. The irradiation-induced inactivation of nucleic acids may actually be accompanied with modifications of chemically reactive polyunsaturated fatty acids, known to be important mediators of platelet functions. Thus, here we investigated eicosanoids and related fatty acids released upon treatment and during platelet storage for 7 days, complemented by the analysis of functional and metabolic consequences of these treatments. In contrast to gamma-irradiation, here we demonstrate that UVA treatment attenuated the formation of ALOX12-products such as 12-HETE and 12-HEPE but induced the formation of trans-arachidonic acids in addition to 11-HETE and HpODEs. Metabolic and functional issues like glucose consumption, lactate formation, platelet aggregation and clot firmness hardly differed between the two treatment groups. <i>In vitro</i> synthesis of trans-arachidonic acids (trans-AA) out of arachidonic acid in the presence of β-mercaptoethanol suggested that thiol radicals formed by UVA treatment are responsible for the INTERCEPT-specific effects observed in platelet concentrates. It is plausible to assume that trans-AA and other UVA-induced molecules may have specific biological effects on the recipients, which need to be addressed in future studies. <h3>Key points</h3> A previously unrecognized radical mechanisms for the generation of trans-fatty acids by UVA was identified Irradiation with UVA was found to immediately affect the generation of polyunsaturated fatty acid oxidation products
Pertussis toxins, other antigens become likely targets for genetic engineering
Authors: C. Marwick
Journal: JAMA (1990)

GENETICALLY engineered pertussis vaccines have yet to be fully tested clinically. But early human, animal, and in vitro studies indicate effectiveness in reducing toxic effects due to<i>Bordetella pertussis</i>. "These are the vaccines of the future, no question," says Rino Rappuoli, PhD, Sclavo Research Center, Siena, Italy, who spoke at the Sixth International Symposium on Pertussis that was held at the National Institutes of Health, Bethesda, Md. The licensed pertussis vaccines consist of inactivated whole cells of the organism. Although highly effective, they have been associated with neurologic complications. While the evidence continues to mount that these complications are extremely rare, if they occur at all, it has affected the public's acceptance of pertussis immunization. This led to the development, originally in Japan, of acellular vaccines containing only purified and chemically inactivated portions of the bacterium. These have been tested in the field, most recently in Sweden (<i>JAMA</i>. 1988;259:2057-2059). Unfortunately,
PHOTODYNAMIC ACTION.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
On the Making of a Clinical Nutritionist
Authors: R. E. Olson
Journal: Annual Review of Nutrition (1996)

Clinical nutrition may be defined as the application of the principles of nutrition science and medical practice to the diagnosis, treatment, and prevention of human disease caused by the deficiency, excess, or metabolic imbalance of nutrients. At present, many physicans do not appreciate the great traditions established by their forebears in this field (Hippocrates, Lind, Eijkman, Glisson, Casal, Livingstone, Hopkins, and Goldberger). They have tended to avoid nutritional problems, plead ignorance of nutrition principles, and delegate the nutritional care of their patients to paramedical personnel. Only by changing this situation can members of the medical profession offer adequate care to their patients. In this chapter, I have attempted to present the duties and responsibilities of a clinical nutritionist in an academic environment. A well-trained academician in such a position can improve the education of medical students in nutrition, attract well-motivated graduates into nutrition training programs, and establish clinical nutrition as a bona fide subspecialty of medicine.
Officials of the Association 1983-1984
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiovascular Disease
Authors: Joel M. Gore
Journal: JAMA (1994)

No one can dispute that thrombolytic therapy saves lives. However, the question remains, which is the most cost-effective agent: streptokinase (SK) or tissue-type plasminogen activator (t-PA)? Several studies have suggested that t-PA is more effective than SK; however, given the fact that t-PA is nearly 10 times as expensive as SK, further clinical trials were performed to verify that t-PA is more effective. The results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) study, which were reported in the fall of 1993,<sup>1,2</sup>strongly suggest that t-PA is more effective than SK. The GUSTO study enrolled 41 021 patients from 1081 hospitals in 15 countries and compared the following four treatment strategies for acute myocardial infarction (AMI): (1) SK plus subcutaneous heparin; (2) SK plus intravenous (IV) heparin; (3) combined t-PA, SK, and IV heparin; and (4) accelerated t-PA (administration of t-PA over
Centenary of the Coombe Lying-In Hospital.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluating the superior vena cava syndrome
Authors: D. S. Shimm
Journal: JAMA (1981)

We reviewed the records of 28 patients with superior vena cava syndrome (SVCS) between 1973 and 1978 to establish the risk from invasive diagnostic procedures and the therapeutic value of the information obtained. Of 23 patients, this syndrome was the initial manifestation in 18. Bronchoscopy with endobronchial biopsy, thoracentesis, pleural biopsy, lymph node biopsy, and, in one patient, thoracotomy were performed without major complications. Small cell undifferentiated carcinoma of the lung was found in seven of the 18 patients with SVCS as the initial manifestation of their disease. We believe that carefully performed invasive diagnostic procedures can be carried out safely. Furthermore, accurate histological diagnosis assumes major importance with the development of effective chemotherapy for small cell undifferentiated carcinoma of the lung. (<i>JAMA</i>1981;245:951-953)
An Existential Oncologist
Authors: Lidia Schapira
Journal: Journal of Clinical Oncology (2002)

Article Tools THE ART OF ONCOLOGY: WHEN THE TUMOR IS NOT THE TARGET Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.9.2407 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11981017 An Existential Oncologist Lidia SchapiraxLidia SchapiraSearch for articles by this author Show More From the Beth Israel Deaconess Medical Center, Brookline, MA. https://doi.org/10.1200/JCO.2002.20.9.2407 Full Text PDF Figures and Tables "An Existential Oncologist." Journal of Clinical Oncology, 20(9), pp. 2407–2408© 2002 by American Society of Clinical Oncology
Anopheles aegypti?
Authors: Vernon P. Link
Journal: JAMA (1969)

<h3>To the Editors—</h3> On April 14, '69 Ignoring the anophelineThe Journalof the AMA Averred that someone did away With vectors of malariay,<i>Aedes aegypti</i> Says International Events: Eradication, in a sense, From Nicaragua to Peru Leaves us with nothing more to do To end malaria's loup-garou,<i>Aedes aegypti</i>. It's certain, in this hemisphere Plasmodia can't disappear; Chills and fever don't subside From use of an insecticide On paludism's mosquito bride,<i>Aedes aegypti</i>. If Walter Reed were still about, And Carlos Finlay, then, no doubt, They'd realize that to confuse Malaria with yellow jack Serves to belittle and abuse,<i>Aedes aegypti</i>.
Front &amp; Back Matter
Authors: Anna Muntingh, Christina van der Feltz-Cornelis, Harm van Marwijk, Philip Spinhoven, Willem Assendelft, Margot de Waal, Herman Adèr, Anton van Balkom, Cynthia L. Arfken, Richard Balon, Rebecca Jing Hou, Samuel Yeung-Shan Wong, Benjamin Hon-Kei Yip, Anchor T.F. Hung, Herman Hay-Ming Lo, Peter H.S. Chan, Cola S.L. Lo, Timothy Chi-Yui Kwok, Wai Kwong Tang, Winnie W.S. Mak, Stewart W. Mercer, S. Helen Ma, Alexandra E. Dingemans, Unna N. Danner, Judith M. Donker, Jiska J. Aardoom, Floor van Meer, Karin Tobias, Annemarie A. van Elburg, Eric F. van Furth, Eliana Tossani, Jo Magne Ingul, Tore Aune, Hans M. Nordahl, Giovanni A. Fava, Carol D. Ryff, Esther L. Meerwijk, Sandra J. Weiss, Satz Mengensatzproduktion, Druckerei Stückle, Druckerei Stückle
Journal: Psychotherapy and Psychosomatics (2013)
Abstract 17442: Effects of Small Conductance Ca2+-activated K+ Channels on Cardiogenesis in Human Induced Pluripotent Stem Cells
Authors: Imju Jeong, Sergey Yechikov, Jessica Gluck, Deborah K Lieu
Journal: Circulation (2015)

Human induced pluripotent stem cells (hiPSCs) with the ability to form all somatic cells can generate pacemaking cardiomyocytes (CMs) for engineering of biological pacemakers. However, differentiation efficiency of hiPSCs into pacemaking cardiomyocytes is merely at 5% of the total CMs. Membrane potential of a cell can alter cell fate. Activation of small conductance Ca2+-activated K+ channels (SKs) has been shown to induce membrane hyperpolarization. In this study, we demonstrated that SKs are present and functional in hiPSCs and their differentiation progeny. Addition of SK activator (EBIO or CyPPA) hyperpolarized hiPSCs and differentiating hiPSCs 2 and 5 days post-differentiation by -2.5±0.97, -22.7±1.8 and -13.6±3.3 mV, respectively. The magnitude of hyperpolarization exhibited dose-dependency to SK activator in differentiating hiPSCs 2 days post-differentiation. Activation of SK channels by EBIO or CyPPA on day 2-3 from the onset of differentiation significantly upregulated the expression of Islet (Isl)1, a marker for a subset of cardiac progenitor cells that are known to form the sinoatrial node where the pacemaking cardiomyocyte reside. The number of Isl1-positive cells in differentiating hiPSCs with SK activation on day 2-3 has also increased relative to control. Our findings indicate that the activation of SK channels at an appropriate treatment time and length results in a facilitated increase in the differentiation of hiPSCs to pacemaking cardiomyocyte precursors.
Where are all the tranquilizer junkies?
Authors: E. R. Gonzalez
Journal: JAMA (1983)

In some quarters, "diazepam" remains a dirty word. Although its position as the most-prescribed drug in the United States has been usurped by cimetidine, this agent and its chemical siblings still symbolize overprescription and overmedication to many. Television producer Barbara Gordon captured the quintessence of consumer concern in the afterword to a book describing the protracted mental illness that occurred after her abrupt withdrawal from 30 mg of diazepam per day: "The number of Americans being given large doses of tranquilizers by their internists, obstetricians, dentists—let alone psychiatrists—is staggering.... Because of my strong feelings about medical mismanagement, because of the prevalence of drug abuse—and the soft-core prescription-pad variety is drug abuse all the same—I felt I had to tell my story" (<i>I'm Dancing as Fast as I Can</i>. New York, Harper &amp; Row Publishers Inc, 1979, p 311). But who are those soft-core drug abusers, mismanaged and addicted to the
Studien ueber die bei Peritonäalen Infektionen Appendi-kulären Ursprungs Vorkommenden Sauerstofftoleranten Sowie Obligat Anaëroben Bakterienformen mit besonderer Berücksichtigung ihrer Bedeutung für die Pathogenese derartiger Peritonitiden.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MALPIGHI, SWAMMERDAM AND LEEUWENHOEK.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety of Vaccinations
Authors: Gary L. Freed
Journal: JAMA (1996)

ON SEPTEMBER 17,1994, Heather Whitestone was chosen as Miss America, the first ever with a disability. Her deafness has been the subject of much media attention. On September 16, 1994, the<i>Atlanta Constitution</i>ran a story in its front section about Whitestone stating, "At age 18 months, [she] almost died from an adverse reaction to a routine DPT (diphtheria, pertussis, tetanus) vaccination. It wiped out all but a tiny sliver of her hearing."<sup>1</sup>On September 18, the<i>New York Times</i>ran an Associated Press story in its first section stating "Miss Whitestone... lost her hearing at 18 months because of a reaction to a diphtheria-tetanus shot."<sup>2</sup>On September 19 the<i>New York Times</i>ran another story ascribing her deafness to a vaccination.<sup>3</sup>Not until September 26 did the<i>New York Times</i>publish a story stating that Whitestone's deafness was not due to a vaccination but actually resulted
Mortality from pulmonary embolism
Authors: J. R. Johnson
Journal: JAMA (1986)

<h3>To the Editor.—</h3> The well-written comments by Paul Quartararo<sup>1</sup>in the Feb 21 issue of<i>JAMA</i>, discussing the cover, a painting by Edward Hicks, will certainly stimulate discussion—especially among the historians who read it. Quartararo writes: "Hicks' primary occupation was that of a Quaker minister; he had started painting designs on carriages to supplement his meager income." Hicks was a coachmaker's apprentice and as a boy learned to paint pictures as he moved from coloring coaches to painting signs, furniture, and utensils. This was before he joined the Society of Friends.<sup>2,3</sup>In 1815, after failing at farming, he returned full time to commercial painting. At the age of 31 he had become a Friend's minister but continued to work at his profession, writing in 1827, at the age of 47, "I am now employing four hands, besides myself, in coach, sign, and ornamental painting and still more in
Conditioned skeletal muscle: new assist for failing heart?
Authors: C. A. Raymond
Journal: JAMA (1986)

Each year, an estimated 10,000 patients experience irreversible congestive heart failure secondary to myocardial fibrosis. All of the available therapies— digitalis and afterload reduction agents, transplants, and mechanical assist devices—have shortcomings. Now, investigators in the United States and Europe have developed modified skeletal muscles that they believe may eventually provide a fourth therapeutic alternative. The approach involves electrically conditioning skeletal muscle to develop fatigue resistance, and then using it as autogenous grafts or ventricular assist pumps that augment aortic diastolic pressure. Proponents contend that this will circumvent rejection problems and reduce the risk and cost of heart surgery. Skeletal muscle grafts have already been tried clinically in this country and in France. The American surgeon, George J. Magovern, MD, chief of surgery at Allegheny General Hospital, Pittsburgh, says that his patient could have lived without the muscle graft, but that it has improved her quality of life. He cautions that
Heart to Heart
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Benzodiazepine prescribing in a family medicine center
Authors: J. D. Hasday
Journal: JAMA (1981)

We monitored benzodiazepine prescribing in a family medicine center for two years. A total of 1,886 prescriptions were written for four benzodiazepines in the following order of frequency: diazepam, chlordiazepoxide, oxazepam, clorazepate. The most frequent diagnostic indications were anxiety neurosis, hysterical neurosis, and vertebral column disorders. Most benzodiazepine recipients were women, but for alcohol abuse more prescriptions were written for men. More than half of the patients were between the ages of 25 and 44 years. Although daily doses were reduced for elderly patients, the course of therapy was often longer. Female physicians wrote fewer prescriptions for men than for women. More prescriptions for benzodiazepines were written during the summer months than during the rest of the year, and more were written on weekdays than on the weekend. Benzodiazepine recipients were given more prescriptions for other drugs than were the rest of the patients in the practice. (<i>JAMA</i>1981;246:1321-1325)